The Lupus Research Alliance is excited to announce that a potential new medicine for lupus—anifrolumab—reduced disease activity versus placebo in a second Phase III study. Anifrolumab is a therapeutic antibody that blocks type I interferons, a molecule that promotes lupus inflammation. The LRA was ahead of the curve by funding more than 15 studies that … Potential New Treatment in Phase III Trial
The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel J. Wallace, MD joins as a new member of its distinguished Board of Directors. A renowned leader in clinical research and care for lupus and other rheumatologic diseases, Dr. Wallace is Medical Director of the Wallace Rheumatic Study Center and Associate … Welcoming Daniel J. Wallace, MD to Lupus Therapeutics
Many dynamics of lupus contribute to the fact that its complexities have eluded the scientific community—but new hope may come from patients themselves. This is why Lupus Therapeutics piloted the Patient Advocates for Lupus Studies (PALS) program in the Summer of 2019. PALS focuses on reaching diverse populations to improve their knowledge and awareness of … Peer-to-Peer Involvement Advances Scientific Exploration
The Lupus Research Alliance (LRA)—going bold and thinking big—has once again shifted the status quo of lupus research by becoming the first and only lupus organization to conduct its own clinical trials. How did we achieve what once seemed unobtainable? We created Lupus Therapeutics (an LRA affiliated organization) and since the program started in 2017, … Lupus Therapeutics Shifting the Paradigm
TAK-079A Study to Evaluate the Safety of TAK-079 PAISLEY-SLEA Phase II study to evaluate a novel, oral therapy in SLE ORKIDSA study to evaluate the effects of krill oil in SLE LOTUSA Phase III study to evaluate Stelara® in SLE DIVINEA study to evaluate a novel imaging procedure to access Lupus Nephritis (LN) RIFLEA study … 10 Lupus Therapeutics Studies Currently Underway
Caroline Donovan, Manager of Patient Engagement at Lupus Research Alliance (LRA) affiliate Lupus Therapeutics (LT) took part in a panel discussion at the DIA 2019 (Drug Information Association) annual meeting, aimed at finding ways to make sure that diverse groups of patients can make informed choices about joining a clinical trial. Ms. Donovan explained that … Lupus Research Alliance and Lupus Therapeutics – Leading Voices in Trial Diversity
Making new and efficacious lupus therapies available to patients has long been a major focus of the Lupus Research Alliance, and today we’ve taken an important step toward that aim. Based on a breakthrough discovery made by Betty Diamond, MD of Feinstein Institutes for Medical Research, Meggan Mackay, MD, MS, also at Feinstein, will conduct a … Taking Scientific Discovery: From Lab Bench to You